PHIO PHARMACEUTICALS CORP. Financing Cash Flow
PHIO PHARMACEUTICALS CORP. (PHIO) reported Financing Cash Flow of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $12.40M, a 815.50% increase year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $2.02M, a 23.55% decline year-over-year.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for fiscal 2025 was $23.64M, a 491.59% increase from fiscal 2024.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for fiscal 2024 was $4.00M, a 46.09% decline from fiscal 2023.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for fiscal 2023 was $7.41M.
- PHIO PHARMACEUTICALS CORP. net cash provided by (used in) financing activities for fiscal 2022 was -$26.00K, a 100.12% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 111 month | Net Cash Provided by (Used in) Financing Activities 114 month | Net Cash Provided by (Used in) Financing Activities 117 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $0.00 10-Q · filed 2026-08-06 | $12.40M derived: sum of 3 quarters · filed 2026-08-06 | $14.43M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-07 | $12.40M derived: sum of 2 quarters · filed 2026-05-07 | $14.43M derived: sum of 3 quarters · filed 2026-05-07 | $14.47M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-12-31 | $12.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $14.43M derived: sum of 2 quarters · filed 2026-03-05 | $14.47M derived: sum of 3 quarters · filed 2026-08-06 | $23.64M 10-K · filed 2026-03-05 | |||||
| 2025-09-30 | $2.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.06M derived: sum of 2 quarters · filed 2026-08-06 | $11.23M 10-Q · filed 2025-11-13 | $12.59M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-06-30 | $40.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $9.21M 10-Q · filed 2026-08-06 | $10.57M derived: sum of 3 quarters · filed 2026-08-06 | $13.21M derived: sum of 4 quarters · filed 2026-08-06 | |||||
| 2025-03-31 | $9.17M 10-Q · filed 2026-05-07 | $10.53M derived: sum of 2 quarters · filed 2026-05-07 | $13.17M derived: sum of 3 quarters · filed 2026-05-07 | $13.17M derived: sum of 4 quarters · filed 2026-05-07 | |||||
| 2024-12-31 | $1.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $4.00M derived: sum of 2 quarters · filed 2026-03-05 | $4.00M derived: sum of 3 quarters · filed 2026-03-05 | $4.00M 10-K · filed 2026-03-05 | |||||
| 2024-09-30 | $2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.65M derived: sum of 2 quarters · filed 2025-11-13 | $2.64M 10-Q · filed 2025-11-13 | $5.04M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$4.00K 10-Q · filed 2025-08-14 | $2.40M derived: sum of 3 quarters · filed 2025-08-14 | $2.40M derived: sum of 4 quarters · filed 2025-08-14 | |||||
| 2024-03-31 | -$4.00K 10-Q · filed 2025-05-15 | $2.40M derived: sum of 2 quarters · filed 2025-05-15 | $2.40M derived: sum of 3 quarters · filed 2025-05-15 | $7.45M derived: sum of 4 quarters · filed 2025-05-15 | |||||
| 2023-12-31 | $2.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.40M derived: sum of 2 quarters · filed 2025-03-31 | $7.45M derived: sum of 3 quarters · filed 2025-03-31 | $7.41M 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $5.05M derived: sum of 2 quarters · filed 2024-11-14 | $5.01M 10-Q · filed 2024-11-14 | $5.01M derived: sum of 4 quarters · filed 2024-11-14 | |||||
| 2023-06-30 | $5.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $5.01M 10-Q · filed 2024-08-14 | $5.01M derived: sum of 3 quarters · filed 2024-08-14 | $5.01M derived: sum of 4 quarters · filed 2024-08-14 | |||||
| 2023-03-31 | -$38.00K 10-Q · filed 2024-05-09 | -$36.00K derived: sum of 2 quarters · filed 2024-05-09 | -$39.00K derived: sum of 3 quarters · filed 2024-05-09 | -$39.00K derived: sum of 4 quarters · filed 2024-05-09 | |||||
| 2022-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$1.00K derived: sum of 2 quarters · filed 2024-04-01 | -$1.00K derived: sum of 3 quarters · filed 2024-04-01 | -$26.00K 10-K · filed 2024-04-01 | |||||
| 2022-09-30 | -$3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$3.00K derived: sum of 2 quarters · filed 2023-11-09 | -$28.00K 10-Q · filed 2023-11-09 | -$29.00K derived: sum of 4 quarters · filed 2023-11-09 | |||||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$25.00K 10-Q · filed 2023-08-10 | -$26.00K derived: sum of 3 quarters · filed 2023-08-10 | -$26.00K derived: sum of 4 quarters · filed 2023-08-10 | |||||
| 2022-03-31 | -$25.00K 10-Q · filed 2023-05-11 | -$26.00K derived: sum of 2 quarters · filed 2023-05-11 | -$26.00K derived: sum of 3 quarters · filed 2023-05-11 | -$26.00K derived: sum of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$1.00K derived: sum of 2 quarters · filed 2023-03-22 | -$1.00K derived: sum of 3 quarters · filed 2023-03-22 | $21.72M 10-K · filed 2023-03-22 | |||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $0.00 derived: sum of 2 quarters · filed 2022-11-10 | $21.72M 10-Q · filed 2022-11-10 | $21.72M derived: sum of 4 quarters · filed 2022-11-10 | |||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $21.72M 10-Q · filed 2022-08-11 | $21.49M 10-Q · filed 2021-08-12 | $21.72M derived: sum of 3 quarters · filed 2022-08-11 | $21.71M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $21.72M 10-Q · filed 2022-05-12 | $21.49M 10-Q · filed 2021-05-13 | $21.72M derived: sum of 2 quarters · filed 2022-05-12 | $21.71M derived: sum of 3 quarters · filed 2022-05-12 | $29.32M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$17.00K derived: sum of 2 quarters · filed 2022-03-22 | $7.59M derived: sum of 3 quarters · filed 2022-03-22 | $16.13M 10-K · filed 2022-03-22 | |||||
| 2020-09-30 | -$17.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $7.59M derived: sum of 2 quarters · filed 2021-11-10 | $16.13M 10-Q · filed 2021-11-10 | $16.90M derived: sum of 4 quarters · filed 2021-11-10 | |||||
| 2020-06-30 | $7.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $16.15M 10-Q · filed 2021-08-12 | $16.91M derived: sum of 3 quarters · filed 2021-08-12 | $16.86M derived: sum of 4 quarters · filed 2021-08-12 | |||||
| 2020-03-31 | $8.54M 10-Q · filed 2021-05-13 | $9.30M derived: sum of 2 quarters · filed 2021-05-13 | $9.25M derived: sum of 3 quarters · filed 2021-05-13 | $9.27M derived: sum of 4 quarters · filed 2021-05-13 | |||||
| 2019-12-31 | $766.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $711.00K derived: sum of 2 quarters · filed 2021-03-25 | $729.00K derived: sum of 3 quarters · filed 2021-03-25 | $772.00K 10-K · filed 2021-03-25 | |||||
| 2019-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | -$37.00K derived: sum of 2 quarters · filed 2020-11-10 | $6.00K 10-Q · filed 2020-11-10 | $13.40M derived: sum of 4 quarters · filed 2020-11-10 | |||||
| 2019-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $61.00K 10-Q · filed 2020-08-12 | $13.45M derived: sum of 3 quarters · filed 2020-08-12 | $13.38M derived: sum of 4 quarters · filed 2020-08-12 | |||||
| 2019-03-31 | $43.00K 10-Q · filed 2020-05-12 | $13.43M derived: sum of 2 quarters · filed 2020-05-12 | $13.37M derived: sum of 3 quarters · filed 2020-05-12 | $17.93M derived: sum of 4 quarters · filed 2020-05-12 | |||||
| 2018-12-31 | $13.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $13.32M derived: sum of 2 quarters · filed 2020-03-26 | $17.89M derived: sum of 3 quarters · filed 2020-03-26 | $18.82M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | -$68.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $4.50M derived: sum of 2 quarters · filed 2019-11-12 | $5.43M 10-Q · filed 2019-11-12 | $5.80M derived: sum of 4 quarters · filed 2019-11-12 | |||||
| 2018-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $5.50M 10-Q · filed 2019-08-12 | $5.87M derived: sum of 3 quarters · filed 2019-08-12 | $5.79M derived: sum of 4 quarters · filed 2019-08-12 | |||||
| 2018-03-31 | $932.00K 10-Q · filed 2019-05-14 | $1.30M derived: sum of 2 quarters · filed 2019-05-14 | $1.22M derived: sum of 3 quarters · filed 2019-05-14 | ||||||
| 2017-12-31 | $366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-27 | $292.00K derived: sum of 2 quarters · filed 2019-03-27 | $292.00K 10-K · filed 2019-03-27 | ||||||
| 2017-09-30 | -$74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | -$74.00K 10-Q · filed 2018-11-14 | |||||||
| 2017-06-30 | $0.00 10-Q · filed 2018-08-14 | ||||||||
| 2013-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | $21.00K derived: sum of 2 quarters · filed 2014-03-28 | $23.00K derived: sum of 3 quarters · filed 2014-03-28 | $15.67M 10-K · filed 2014-03-28 | |||||
| 2013-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | -$5.00K derived: sum of 2 quarters · filed 2013-11-14 | $15.64M 10-Q · filed 2013-11-14 | $15.64M derived: sum of 4 quarters · filed 2014-05-14 | |||||
| 2013-06-30 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $15.65M 10-Q · filed 2013-08-14 | $15.64M derived: sum of 3 quarters · filed 2014-05-14 | $15.64M derived: sum of 4 quarters · filed 2014-05-14 | |||||
| 2013-03-31 | $15.64M 10-Q · filed 2014-05-14 | $15.64M derived: sum of 2 quarters · filed 2014-05-14 | $15.63M derived: sum of 3 quarters · filed 2014-05-14 | $24.30M derived: sum of 4 quarters · filed 2014-05-14 | |||||
| 2012-12-31 | -$3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-28 | -$10.00K derived: sum of 2 quarters · filed 2014-03-28 | $8.66M derived: sum of 3 quarters · filed 2014-03-28 | $9.67M 10-K · filed 2014-03-28 | |||||
| 2012-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $8.66M derived: sum of 2 quarters · filed 2013-11-14 | $9.67M 10-Q · filed 2013-11-14 | $65.15M 10-Q · filed 2012-11-13 | |||||
| 2012-06-30 | $8.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-14 | $9.68M 10-Q · filed 2013-08-14 | $65.16M 10-Q · filed 2012-08-14 | ||||||
| 2012-03-31 | $1.01M 10-Q · filed 2013-05-15 | $56.49M 10-Q · filed 2012-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |